Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betty's Eddies is a branded line of cannabis-infused fruit chews developed and marketed by MariMed. It is a botanical, orally administered edible product rather than a conventional pharmaceutical, and uses full-spectrum cannabis oil formulated into chewable fruit confections made with plant-derived ingredients. The pharmacology depends on the specific product variant, which may contain tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, cannabichromene, tetrahydrocannabivarin, or combinations of these cannabinoids. Its intended activity is mediated primarily through modulation of the endocannabinoid system, especially cannabinoid receptors, with different formulations positioned for wellness-oriented uses such as sleep support, discomfort relief, stress reduction, or energy support. Because Betty's Eddies is a brand family with multiple cannabinoid compositions rather than a single standardized drug substance, it is best characterized as a cannabis edible product line.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Betty's Eddies.